Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), is one of the deadliest cancers with a five-year survival rate of <10%. Because of its high grade and lack of known effective standard therapies, recent clinical trials have utilized novel approaches, including immunotherapy-based treatments, targeted agents and combinations.
Immunotherapy: Although modestly successful at best, the first immune checkpoint inhibitors and CAR-T cell therapies are currently under clinical testing in combination with other anti-neoplastic modalities due to the inherently immunounsupprotive microenvironment of PDAC. For example pembrolizumab (Keytruda) is being tested for use in patients with tumor-high microsatellite instability (MSI), whole trials are looking at how to combine immunotherapy with chemotherapy or stromal-targeting drugs to increase immune cell infiltration.
Targeted Therapy: This category includes therapies which are designed to target specific mutations in PDAC, including the all too famous KRAS G12D mutation found in more than 90% of cases. One approach that is being tested in trials for drugs like MRTX1133 is to interfere with this mutation's part in driving cancer growth. Further, PARP inhibitors like olaparib (Lynparza) have given a glimmer of hope for BRCA mutation positive patients.
Combination Therapies: Viable strategies combine chemotherapies like FOLFIRINOX with new agents like immune checkpoint inhibitors or stroma-modifying drugs. These combination strategies are designed to improve drug effectiveness and bypass the dense, fibrotic tumor microenvironment that is partly responsible for the high failure rate of therapies in pancreatic cancer.
|
Mechanism of Action |
Key Drugs |
|---|---|
|
Immunotherapy |
Pembrolizumab (Keytruda) |
|
KRAS Inhibition |
MRTX1133 |
|
PARP Inhibition |
Olaparib (Lynparza) |
|
Cytotoxic Chemotherapy |
FOLFIRINOX, Gemcitabine |
|
Combination Therapy |
FOLFIRINOX + Pembrolizumab, Stroma-modifying agents |
Pancreatic cancer is the most lethal of all forms of cancer, mainly due to the high aggressiveness of pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all cases. Pancreatic cancer kills over 500,000 people globally each year and is only expected to get more common due to lifestyle changes and an ageing world population.
The disease presents in a late-stage diagnosis, with as many as 80% of patients already having advanced or metastatic disease at the time of their original identification.
Geographic distribution and demographic characteristics
The incidence of pancreatic cancer also varies by region. The highest incidences of OCNA in the population were reported for Asia, and specifically Japan (age-standardised rate 0·407) and China (0·382), and they presented slightly higher age-standardised ratesbut low numbers in Europe and North America. Lifestyle changes, more screening for a recommendation and populations aging contribute to these total.
In the US, it is projected that by 2024 about 64,000 new cases will be identified each year.
Pancreatic cancer also arises in other parts of South America and Australia at region-specific minimum levels nearing several advances annually.
Many risk factors are related to an increased risk of pancreatic cancer. Most cases are among people 65 or older, and age is a chief risk factor. Diagnosis most commonly occurs in those aged over 70, with the median age at diagnosis being 70 years.
Men are slightly more at risk than women, and certain racial and ethnic groups such as African Americans show higher incidence rates.
Diabetes and chronic pancreatitis.
Smoking: Both past and current smokers have a dramatically increased risk.
Obesity There is a higher risk of pancreatic cancer in men with BMI over 30.
Genetic predisposition including inherited mutations, such as BRCA1/2, PALB2 and Lynch Syndromes (up to 10% of cases)
Pancreatic cancer (PC) is a highly lethal form of malignancy, and its 5-year survival rate worldwide fluctuates between 2% and 10% [3]
This poor survival is explained by the fact that disease often presents late (stage IV),we only have limited effective forms of screening and because tumor rapidly metastasize early in their natural history. Patients with early stage diagnosis and resectable cancers enjoy a better prognosis, but recurrence is common despite surgery.
Given the global ageing population, overall pancreatic cancer incidence is projected to rise. Rate of pancreatic cancer death increase for men, doctor discovery could be step toward ending itExperts say by 2030 pancreatic cancer will be second most common cause of cancer deaths worldwide.
This trend underscores an increasing demand for innovations in diagnosis, treatment options, and personalized approaches to therapy that will drive improved outcomes to patients.
In the future, personalized medicine strategies will be further refined, especially for KRAS and BRCA mutations to determine treatment of greatest benefit. The incorporation of immunotherapies as well as combination treatment programs are anticipated to enhance person results, and the identification of biomarkers will certainly influence individualized therapy biuss. Accessibility is still a robust obstacle, treatment costs are high, and regulatory constraints inhibit immediate assistance especially in more disadvantaged sectors.
Introduction
1.1 Overview of Pancreatic Cancer
1.2 Importance of Clinical Trials in Advancing Treatment
Epidemiology of Pancreatic Cancer
2.1 Incidence and Prevalence
2.2 Geographic Distribution and Demographics
2.3 Risk Factors and Lifestyle Influences
2.4 Mortality and Survival Statistics
Innovative Approaches in Pancreatic Cancer Clinical Trials
3.1 Immunotherapy Advances
3.2 Targeted Therapy for KRAS and BRCA Mutations
3.3 Combination Therapies and Novel Agents
Mechanisms of Action in Pancreatic Cancer Treatment
4.1 Immune Checkpoint Inhibitors
4.2 KRAS and PARP Inhibition
4.3 Cytotoxic Chemotherapy
4.4 Stroma-Targeting and Angiogenesis Inhibitors
Detailed Analysis of Ongoing Clinical Trials
5.1 Phase-wise Distribution of Pancreatic Cancer Trials
5.2 Results from Key Studies
5.3 Geographical Distribution of Research and Patient Recruitment
Patient Population and Treatment Response
6.1 Characteristics of Patient Populations
6.2 Impact of Genetics and Biomarkers on Treatment Response
6.3 Personalized Medicine and Targeted Approaches
Challenges and Implications for Future Research
7.1 Barriers in Treatment Efficacy and Drug Resistance
7.2 Addressing Tumor Microenvironment and Drug Delivery Issues
7.3 Access to Clinical Trials and Global Disparities in Treatment
Market Impact and Financial Considerations
8.1 Growth of Immunotherapies and Targeted Therapies
8.2 Cost and Accessibility Challenges in Emerging Markets
8.3 Role of Biosimilars and Generics in Reducing Costs
Conclusion
9.1 Summary of Key Findings
9.2 Future Directions in Pancreatic Cancer Research
Appendix
10.1 Glossary of Terms
10.2 Abbreviations and Acronyms
10.3 References and Data Sources
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
